InnoCare Pharma Limited
( )
( 9969)
625,404 1,043,033
198,199 217,938
(438,611) (298,463)
(639,139) (721,584)
(181,556) (139,815)
(291,167) (1,271)
(893,727) (66,679)
(473,691) 2,630
1
214.7
163.6% 565.9
625.4
1,043.0 417.6
776.0
217.9
198.2
(i) 57.1
(ii) 0.07
8.4 8.5 (iii)
16.3 29.9 46.2
(iv) 135.1 1.8
136.9
1,161.1
1,550.5
(i)
57.1 290.6
(ii) 304.5 115.4
419.9 273.0
2.5 (iii)
298.5 140.1
438.6
66.7 893.7
2.6 473.7
2
(893,727) (66,679)
290,559 (57,135)
129,477 126,444
(473,691) 2,630
3
13
2 30
B T
B T
MS II 12
BTK
II 12
Gd +T1
80 QD 92.1%
(p=0.0006)
SLE IIa
SLE
SRI –4
EULAR
CDE SLE
IIb
ITP II
PoC 50 x 109 L
7
36.4% 33 12 50
40% 15 6
4
ICP-332
ICP-332 2 TYK2 T
I I
PK/PD
JAK-2 AE
AD II
ICP-488
ICP-488 TYK2 TYK2 JH2
IL-23 IL12 I IFN ICP-
488
I
SAD
MAD
ICP-248
ICP-490 ICP-B02 Tafasitamab
NHL
MM
B
DLBCL
NHL
BTK
565.9 214.7
164%
CSCO
NMPA
MZL NDA
CLL/SLL
III
5
MCL II
NDA
-1 PD-1
EHA
NHL DLBCL
MCD B DLBCL
III
R-CHOP R-CHOP
R-CHOP MCD DLBCL
ASCO 14
CRR 75% 66.67%
ICP-B04 Tafasitamab CD19 (Minjuvi )
Tafasitamab DLBCL
ASCT
DLBCL Tafasitamab
CSCO ASCT DLBCL
Tafasitamab NMPA
ASCT B DLBCL
Tafasitamab
DLBCL
Tafasitamab
DLBCL
6
ICP-B02 (CM355)
ICP-B02 CD20xCD3 I
ICP-B02
B ICP-B02 SC IND
CDE
MM
ICP-490
ICP-490
IND
CDE I
ICP-248
ICP-248 B 2 BCL-2
BCL-2
ICP-248 IND CDE
I
ICP-192 ICP-
723
ICP-192 (Gunagratinib)
ASCO-GI Gunagratinib
CCA IIa I C P -192
Gunagratinib FGFR2
CCA FGFR
(52.9%) CCA ICP-192
I/II
7
ICP-723 (Zurletrectinib)
I 20 DLT II
RP2D 8
NTRK 75% ORR 12 9 PR
RP2D 77.8% ORR 9 7 PR 12
IND CDE
CDE
ICP-189
ICP-B05 ICP-033
ICP-189
ICP-189 SHP2
Ia ICP-189
40 DLT
PK ICP-189 20
1 PR
ICP-B05 (CM369)
ICP-B05 C-C 8 CCR8
IND I
ICP-B05
8
Tafasitamab
163.6% DLBCL CD19
Tafasitamab BLA
13
PoC MS ITP
1L DLBCL-MCD 1L CLL/SLL 1L
MCL MZL WM MCL
ICP-192 SLE
PoC MS PoC
12
ITP II
PoC BTKi
TYK2 ICP-332
ICP-488
CD3xCD20 BCL-2 E3 Ligase CCR8 SHP2
9
CMC
300
90
10
1.0 2.0
B T
Multiple Sclerosis International Federation
MSIF 280 MS Frost & Sullivan
MS 230
317 BTK B MS
BTK
MS
BBB MS BTK
II MS
MS BTK
B
SLE IIa
SLE BTK
ITP NMOSD II
T
ICP-332 ICP-488
T AD SLE LN IBD
B ICP-332 ICP-488 T
11
ICP-248
ICP-490 ICP-B02 Tafasitamab
MM NHL
B MZL
WM CLL/SLL MCL MCD DLBCL
MCL
NHL
ICP-192 ICP-723
ICP-189 ICP-B05 ICP-033
IND
ICP-B02 ICP-B05 Tafasitamab
12
BTK
CLL/
SLL MCL
625.4
565.9 163.6% 250
300
1,500 6,000
DOT
BTK
CSCO CLL/SLL
MCL BTK
DLBCL pCNSL
13
IND Enabling Filed Market
PHIa PHIb PH2* PH2** PH3
CHN
r/r CLL/SLL 2020 12 25
CHN,SG
r/r MCL 2020 12 25
r/r MZL 2022 8 NDA NMPA
r/r WM 2022 NDA NMPA 2022
BTK 1L: CLL/SLL
ICP-022/
Orelabrutinib
1L: MCL
1L: MCD DLBCL
r/r MCL
HK
Tafa + LEN, r/r DLBCL
ICP-B04/
CD19
Tafasitamab
Tafa + LEN + Orela
NHL
ICP-B02 CD3 x CD20 2022 12
ICP-248 BCL-2
2023 3
NHL/ALL
ICP-490 E3 Ligase MM/DLBCL 2022 7
2023 3
ICP-B05 CCR8 Hemato-oncology
NDA
IND Enabling Filed Market
PHIa PHIb PH2* PH2** PH3
II PoC
ICP-022/
BTK
Orelabrutinib
ICP-332 TYK2 – JH1
ICP-488 TYK2 – JH2
ICP-192/ pan-FGFR
Gunagratinib
2023 2
ICP-723/ pan-TRK NTRK
Zurletrectinib
ICP-033 VEGFR, DDR1
ICP-189 SHP2 IND FDA
ICP-B05 CCR8
NDA
14
B T
B T
AD II
Psoriasis I
IBD
T LN
ICP-332 (TYK2i-JH1) CD
ICP-488 (TYK2i-JH2) UC
SLE
IIa IIb
B I IPoC
MS
II PoC
ITP
(BTKi)
NMOSD II
MS: CSU
NMOSD:
ITP:
CSU:
SLE:
AD:
IBD:
LN:
CD:
UC:
(CNS) B
SLE IIa
SLE BTK IIb
MS II PoC
ITP NMOSD II
CSU
T
TYK2 ICP-332 ICP-488
T AD SLE IBD
LN CD UC
B ICP-332 ICP-488 T
15
B
BTK TEC B
BCR B
BTK BTK
MS
MS II
II RMS
OLE RMS 1:1:1:1
4 50 QD 50 BID
80 QD OLE
24
GdE T1 MRI 12
GdE T1 MRI
136 12
Gd+T1 50 QD 71.1%
(p=0.0238) 50 BID 80.8%(p=0.0032) 80
QD 92.1%(p=0.0006)
16
12 Gd+T1
(95% CI)
71.1%,
P=0.0238 80.8%,
P=0.0032 92.1%,
P=0.0006
Placebo Orela 50mg QD Orela 50mg BID Orela 80mg QD
N=34 N=33 N=34 N=35
1CI
QD= BID= p
Pearson
24
RMS II
T1
(1)
Placebo-controlled(N = 136), 24Wk + ext Cumulative Gd+lesionsat Wk12 92.1% 80mg QD InnoCare
BTK
Tolebrutinib Placebo-controlled for 4Wk, with Dose-response for Gd+ (2)
85% 60mg QD Sano
BTK 12Wk cross-over (N=130), 16Wk + ext lesions at Wk 12
75mg qd
Placebo-controlled + open label DMF (N = Cumulative Gd+ lesions at Wk12, Merck
70% (3) (56% at
BTK 267),24Wk + ext 16, 20, and 24 KGaA
75mg bid)
Placebo-controlled + Inf-b1a reference Cumulative Gd+ lesions at (4)
89% 600mg q6mo Roche
CD20 arm (N=218), 24Wk + ext Wk 12, 16, 20, and 24
Placebo-controlled (N=231), 24Wk + Cumulative Gd+ lesions at 65% (5)(6)
60mg q12w Novartis
CD20 ext Wk 12 91% (7)
Placebo-controlled, adaptive, doseranging Dose-response for CUAL at
72% (8) 2mg qd Novartis
S1PR (N = 297), 6m + ext 3 mo
Cumulative Gd+ lesions at Wk12, (9)
Placebo-controlled(N = 257),24Wk + ext 69% 240mg tid Biogen
16, 20, and 24
61% (10)
Cumulative Gd+ lesions
Placebo-controlled (N = 281), 6m + ext 88% at 5mg qd Novartis
S1PR monthly for 6 months
mo. 6
(11)
Placebo-controlled (N = 179), 36Wk + ext # of CUAL per MRI scan 61% 14mg qd Sano
1 www.clinicaltrials.gov; (2)Sanofi’s R&D held on April 23, 2020;(3) MontalbanX, et al. N
Engl J Med 2019; 380:2406-2417;(4) KapposL, et al. Lancet 2011;378:1779-87 (5) Bar-Or
A. et al, Neurology 2018;90:e1805-e1814; (6)Endpoint with full data (0-12 Wks) (7) Post
hoc data (4-12 wks);(8) Selmaj K, et al Lancet Neurol 2013;12:756-767;(9) Kappos L, et al.
Lancet 2008;372(9648):1463-72;(10) Kappos L, et al. N Engl J Med 2006; 355:1124-40;(11)
O’Connor P, et al. Neurology 2006;66(6)
17
MS MS
CNS PK
BBB MS
PK BTK
evobrutinib tolebrutinib evobrutinib
tolebrutinib CNS
(CNS)
T
B
plasmacyte
T
T
AQP4
BTK+
B
MoG B
T
T
B
CSF Conc. ~2h
BTK (mg)
(ng/mL)
Orelabrutinib InnoCare 150 QD 31.3
Evobrutinib Merck KGaA 75 BID 3.212
Tolebrutinib Sano 120 QD 1.871
1 doi: 10.1016/j.msard.2021.103000
2 Multiple Sclerosis and Related Disorders 51 (2021) 103001 Topic: Advances in therapy in
MS; doi: 10.1016/j.msard.2021.103001
18
EAE MS
MOG EAE
EAE
EAE MS
MS DMT FDA
Biolato M, Bianco A, Lucchini M, Gasbarrini A, Mirabella M, Grieco A. The
Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver
Injury: A Narrative Review. CNS Drugs . 2021 Aug;35(8):861-880
26 MS 26 24
22
HBV
DMT Biolato M, Bianco A, Lucchini
M, Gasbarrini A, Mirabella M, Grieco A. The Disease-Modifying Therapies of
Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review. CNS
Drugs. 2021 Aug;35(8):861-880
ALT
19
ALT
β 1 3 6
1 3 6 9 12 C
6 2 C
6
B C
3
48
A
ALT
FDA
II MS
IB ICF FDA iDMC
iHAC FDA
FDA
MS
MS
125
8.125
20
MS
90
B
MS II
MS OLE
MS
BTK
SLE
BTK BCR
B SLE
SLE II
EULAR
SLE 1:1:1:1
12 50 80 100
II
50 80 100 12 SRI-4
35.7% 50.0% 61.5% 64.3%
G C3 C4
21
IIa SLE
IIb
SLE SLE
SLE
1:1:1 25
50 48 SRI-4
SRI-6 C3 C4 dsNDA
12 SRI-4
28.6%
100%
25.8%
90%
80% 14.3%
70% 61.5% 64.3%
60% 50.0%
50%
35.7%
40%
30%
50 80 100
20%
(N=14) (N=14) (N=13) (N=14)
10%
0%
(n=55)
50 80 100
SLE
BTK evobrutinib fenebrutinib
Ringheim, G. E., Wampole, M., & Oberoi, K. (2021) Frontiers in Immunology, 12,
662223 SLE BTK
SLE
ITP
ITP
ITP
T
BTK B ITP B
BTK
ITP ITP
22
ITP II
II ITP
III
50 × 109/L 2
7
22 GC
IVIG 50 75.0%
8 6 36.4% 33
12 40% 15 6 50
II ITP
NMOSD
NMOSD
45-65 0.445/100,000
4.71:1
NMOSD B 4
AQP4 IgG 80% AQP4 IgG BTK B
B
BTK
BTK BTK
NMOSD
IIT II
IIT
23
T –TYK2
ICP-332
ICP-332 TYK2
TYK2 JAK IL-12/IL-23
IFN
T 17 TH17 TH1 B
AD ICP-332 TYK2
400 JAK2 JAK
TYK2 ICP-332
IBD
Pharma Intelligence
12 0.96-22.6% 1.2-17.1%
100
ICP-332
CDE ICP-332 I
I
I PK/PD JAK-2 AE
AD II
I
14 ICP-332 5 320 40 160
QD PK PD 8
ICP-332 6 2 80
ICP-322
ICP-332 5 320 PK Cmax AUClast
14 320
160 QD ICP-332
24
ICP-488
ICP-488 TYK2 JH2 JH2 TYK2
JH2 TYK2 ICP-488
TYK2 TYK2 JH2 IL-23
IL-12 I IFN ICP-488
SLE LN IBD ICP-332 ICP-488
TYK2
I
1 36 SAD
MAD
ICP-488
ICP-248
ICP-490 ICP-B02 Tafasitamab
NHL
MM
DLBCL
NM NHL
(i) (ii) FDA
EMA CD19 Tafasitamab DLBCL (iii)
CD20xCD3 BCL-2 E3 Ligase
(iv)
DLBCL
Tafasitamab BCL-2 E3 Ligase
DLBCL
1L DLBCL MCD Tafasitamab
DLBCL
25
ICP-490
ICP-B05
/CM369
ICP-B02
ICP-248
ICP-490 Orelabrutinib Tafasitamab ICP-248
PTCL/
MM Others CLL/SLL MCL MZL WM FL CNSL DLBCL AML ALL CML Others
CTCL
NHL
850 CLL/SLL MCL
CDE
5
MCL
AE 3
1L CLL/SLL
III CLL/SLL
IRC PFS
51
26
CLL/SLL
II CLL/SLL
150 80 CLL/SLL
47 56.2%
ORR 93.8% CR 30%
1.84 DOR
PFS 48 DOR PFS
56.2% 52.7% CLL/SLL
BTK CR
AE
CLL/SLL
Gazyva FCR
BTKi
7.16 11.07 3 PR/
PR-L SD ORR 75% DCR 100%
BTKi CLL/CLL
1L MCL
III
R-CHOP R-CHOP IRC
iwNHL PFS
22
MCL
II MCL
DOR PFS OS 106
39.43
106
83% 87.8% CT
36.8%
MCL
TRAE
3
27
MCL II
FDA BTD
MCL
WM
WM B M
IgM BTK WM
MYD88L265P
BTK BTK
WM
IRC MRR MRR
ORR DOMR PFS OS
24.90 MRR 80.9% ORR 91.5%
12 DOMR 84.9% 12 PFS 81.2% PFS
AE
3 3
(Lancet eClinicalmedicine)
MZL
II 150
MZL 111
90 MZL 90
MZL 53 PR 43 CR 10
IRC ORR 58.9% 95% CI 48.0 69.2
DOR 34.3 95% CI NA NA
PFS OS IRC 12 PFS OS
82.8% 91% ibrutinib
MZL ORR CR PFS OS
CDE CDE
MZL BTK
NHL DLBCL
1L DLBCL-MCD
DLBCL NHL 100
MCD 1L DLBCL
III R-CHOP
R-CHOP MCD DLBCL
IRC PFS 45
28
40% DLBCL
R-CHOP+X
MCD B
NF-KB BTK
T ITK CD20
NK ADCC
R-CHOP MCD DLBCL
ASCO
R-CHOP MCD DLBCL 14MCD DLBCL
150 8
R-CHOP R-EPOCH 6 RICE R-CHOP R2
CRR 75% 66.67%
MCD DLBCL
MCD DLBCL
Tafasitamab (CD19) ICP-B02 (CD3xCD20) ICP-490 E3
DLBCL
pCNSL
pCNSL
pCNSL ND pCNSL CNSL
pCNSL ORR CR 88.9%
100% 53.9% 61.8% ND pCNSL
PFS
mPFS 6 PFS 63.6% 100%
60% CNSL ORR 60%
86.7% mPFS 9.8 3
mPFS
29
BCR MYD88
MOA BBB 150
21.6 BBB 58.6%
pCNSL
BTK CD20
BTK B BCR
CD20 CDC
ADCC/ADCP
BTK 2 IL-2 -ITK NK
ADCC
(Mol Ther Oncolytics 21: 158-170 2021
BTK BTK
B
ADCC Mol Ther
Oncolytics 21:158-170 2021 Gazyva
ADCC ADCP
CD20 CD19 Tafasitamab
30
CD20 Gazyva(obinutuzumab) ADCC ADCP
BTK
CD20/CD19 B
CD20 Gazyva B
Tafasitamab NHL
II
ICP-B04 (Tafasitamab)
CSCO Tafasitamab
CSCO ASCT
DLBCL DLBCL
CHOP
Tafasitamab
Tafasitamab
Tafasitamab Tafasitamab
NMPA
2 CR
Tafasitamab
18 Tafasitamab DLBCL
Tafasitamab DLBCL II
II
Tafasitamab DLBCL
ORR IRC DCR DoR
PFS TTP TTR OS
24
Tafasitamab B
DLBCL NHL 40% Frost & Sullivan
DLBCL 59
119 NHL/DLBCL Tafasitamab
31
Incyte Tafasitamab Fc
CD19
Tafasitamab FDA
DLBCL DLBCL
ASCT II L-MIND
57.5% ORR(40% CR) 33.5 mOS 43.9 mDoR
Tafasitamab
CD19 B-NHL
B-NHL RE-MIND2
R2 Tafasitamab
Incyte 35 Incyte
82.5
Tafasitamab
Incyte
BTK Tafasitamab
Tafasitamab B
Tafasitamab
ADCC ADCP B CD19
Incyte Tafasitamab
ICP-B02 (CM355)
ICP-B02
CD20xCD3
TDCC ICP-B02
50%
ICP-B02 50%
I/II ICP-B02 NHL
PK I ICP-B02
DLT
5 3+3
DLT ICP-B02 B
ICP-B02 SC IND CDE
32
MM
ICP-490
ICP-490 CRBN E3
TPD
CRL4CRBN-E3 ICP-490 IKZF1
Ikaros IKZF3 Aiolos ICP-490
CRBN E3
Aiolos Ikaros ICP-490
MM B DLBCL
ICP-490 CRNB
ICP-490 ADCC
CD38 daratumumab
ICP-490
DLBCL
ICP-490 MM
IMiD MM
NHL
IND CDE I
ICP-248
ICP-248 B 2 BCL-2
BCL-2 BCL-2
BCL-2
ICP-248
ICP-248 BCL-2
ICP-248 ALL
AML FL CLL DLBCL
BCL-2 10% 20
ICP-248
33
ICP-248 IND CDE
I I
ICP-248 B CLL/SLL
MCL ICP-248
ICP-248 CLL/SLL
ICP-192 ICP-723
ICP-189
ICP-B05 ICP-033
ICP-192 (Gunagratinib)
20
ORR 52.9% DCR 94.1%
ICP-723 (Zurletrectinib)
NTRK
8 ORR 75%
RTKi EGFRi VEGFi KRASi RAFi
MEKi CDK4/6i PD-1/PD-L 1 ICI
ICP-189 ICP-B05
SHP-2 CCR8
34
FGFR ICP-192 TRK ICP-723
SHP2 CCR8 ICP-189 ICP-B05
ICP-033
ICP-192 (Gunagratinib)
Gunagratinib
FGFR FGFR
7.1%
FGFR
Gunagratinib FGFR
FGFR Gunagratinib FGFR
Gunagratinib CCA
IIa ICP-192 18 CCA 17
5.57 ORR 52.9% 17
9 DCR 94.1% 17 16 mPFS
6.93 95% CI 5.42 TRAE
FGFR
Gunagratinib CCA FGR2
(52.9%)
Gunagratinib I/II
II
II ORR 44.4% 9
4 DCR 88.9% 9 8
ICP-723 (Zurletrectinib)
ICP-723 TRK
TRK TRK
NTRK TRK TRK
ICP-723 TRKA/B/C TRKA G595R
G667C ICP-723 TRK
ICP-723 ROS1 ROS1
35
TRK TRKA TRKB TRKC
NTRK1 NTRK2 NTRK3 TRK
NTRK NTRK
NTRK
C-Ros 1
(ROS1)
NSCLC
ROS1 NSCLC
I/II ICP-723 NTRK/ROS1
PK
ASCO
I/II I II
I
II NTRK ROS1
TRK ROS1
I 24 DLT II
RP2D 8
NTRK 75% ORR 12
9 PR 8 77.8% ORR 9 7 PR 6
ROS1 ORR 50%
4 PR
DLT
12 IND CDE
CDE EoP2
36
ICP-189
ICP-189 SHP2
ICP-189
SHP2 RAS-MAPK
PD-1
SHP2
ICP-189
ICP-189
EGFR KRAS MEK PD-1
Ia ICP-189
40 DLT 3 TRAE SAE ICP-189
20 1
PR ICP-189 PK ICP-189
Ib ICP-189
EGFR PD-1
ICP-189 IND FDA
ICP-B05 (CM369)
ICP-B05 C-C 8 CCR8
CCR8 TME T
Tregs CM369 Tregs CCR8 ADCC
Tregs TME
CM369 T
ICP-B05 IND CDE
I ICP-B05
ICP-B05
37
ICP-033
ICP-033 1 DDR1
VEGFR
ICP-033
ICP-033
ICP-033 I
PROTAC XDC
50,000
GMP
NMPA
BTK
30,000
38
CMC
70,381
29.19
MS BTK
90
39
% %
566,755 90.6 214,666 20.6
58,649 9.4 52,404 5.0
– – 775,963 74.4
625,404 100.0 1,043,033 100.0
1,043.0
625.4
352.1 164.0%
566.8
776.0
% %
471,170 97.8 191,008 19.5
10,837 2.2 10,395 1.1
– – 775,963 79.4
482,007 100.0 977,366 100.0
977.4 93.7%
482.0 77.1%
8
40
217.9
198.2
(i) 57.1
(ii) 0.07
8.4 8.5 (iii)
16.3 29.9 46.2
(iv) 135.1 1.8
136.9
721.6
639.1
% %
2,490 0.4 273,026 37.8
196,826 30.8 167,589 23.2
223,095 34.9 136,923 19.0
58,164 9.1 39,428 5.5
43,083 6.7 21,837 3.0
115,481 18.1 82,781 11.5
639,139 100.0 721,584 100.0
(i) 273.0 270.5
2.5
(ii) 167.6 29.2
196.8
(iii) 136.9 86.2 223.1
(iv) 39.4 18.8 58.2
(v) 21.8 21.3 43.1
(vi) 82.8
32.7 115.5
41
139.8
181.6 (i)
47.0 78.0 (ii)
3.6
11.3 (iii) 1.4
6.9 (iv) 9.2
15.8
% %
78,008 43.0 46,964 33.6
34,357 18.9 43,017 30.8
35,159 19.4 35,563 25.4
11,297 6.2 3,637 2.6
6,895 3.8 1,392 1.0
15,840 8.7 9,242 6.6
181,556 100.0 139,815 100.0
298.5
438.6
(i) 126.5
219.4 (ii) 100.7
143.1
% %
219,422 50.0 126,462 42.4
143,105 32.6 100,712 33.7
36,956 8.5 43,999 14.7
39,128 8.9 27,290 9.2
438,611 100.0 298,463 100.0
42
57.1
290.6
51.0
3.4
9.7
0.6
2.6
17.0
46.6
43
127,825 45,273
95,344 116,145
65,322 9,918
313,290 317,059
8,697,927 5,928,716
9,299,708 6,417,111
118,597 84,602
4,242 6,831
727,552 204,886
7,757 12,647
20,112 20,336
1,197,168 –
2,075,428 329,302
7,224,280 6,087,809
7,224.3
8,697.9 127.8
95.3
313.3
727.6 118.6 1,197.2
44
127,822 45,273
3 –
127,825 45,273
116.1 95.3
16.3 16.3
33,557 37,532
44,987 41,363
– 16,340
12,147 17,362
4,653 3,548
95,344 116,145
45
313.3
317.1 304.7
9.9 65.3
111,186 84,459
7,335 121
66 17
10 5
118,597 84,602
90
204.9
727.6
(i) 47.0
104.1 (ii)
41.4
57.0 (iii)
33.1 7.6
(iv) 23.0
51.4 (v)
459.5
46
104,050 46,956
57,014 41,406
32,580 37,360
7,628 33,070
51,391 23,024
– 20,000
459,517 –
15,372 3,070
727,552 204,886
20,112 20,336
459,517 –
1,197,168 –
35,439 47,442
287,761 37,693
– 1,200,564
1,999,997 1,306,035
1,306.0
2,000.0
47
136.3
286.0
430.1
653.2
136.0
284.1
34.2
41.3 SAP
21.4
11.7
51.0
28.0
4.5 19.5
1,197.2
204.9
727.6
84.6
118.6
5,928.7
8,697.9
48
8.95
250,324,000 0.000002
3,883 2,240.4
H.10
37,548,000
15%
322.59
210,508,000 14.45
264,648,217 0.000002
11.03
2,778.82
9,011.2 6,550.5
49
715
(i) 8.5
(ii) 6.6
300
100% 18.8%
17%
1,197.2
287.8
459.5
163.4
50
183
17 1712-1716
51
(i) (ii)
– (i)
(ii) 3.05
(iii) 622 16
–
–
–
13.51(2)
–
13.51B(1)
52
C.2.1
(i)
(ii)
(iii)
53
3.10(2) 3.21
54
2,415.67
1,260.2
52.2%
50% 1,207,835 853,114 441,116 411,998
40% 966,268 812,054 115,853 696,201
*
10% 241,567 63,666 16,350 47,316
2,415,670 1,728,834 573,319 1,155,515
*
(i) (ii)
55
Gaoling Fund L.P. YHG Investment L.P.
Vivo Opportunity Fund, L.P.
210,508,000
16.33% 14.04%
14.45 421.02
3,041.44 210,508,000
14.45
15.72 3,041.84
3,041.44
3,041,440 1,704,498 1,336,942
2,919.07 140.25
2,778.82
545.7
56
1,494,220.6 – 1,494,220.6
116,146.6 – 116,146.6
273,851.4 – 273,851.4
60,952.3 – 60,952.3
833,644.7 – 833,644.7
2,778,815.6 – 2,778,815.6
57
4 625,404 1,043,033
(143,397) (65,667)
482,007 977,366
4 198,199 217,938
(438,611) (298,463)
(639,139) (721,584)
(181,556) (139,815)
(291,167) (1,271)
3,396 (51,014)
(100) (32)
(9,711) (604)
(17,045) (2,642)
(893,727) (20,121)
5 – (46,558)
(893,727) (66,679)
(886,593) (64,545)
(7,134) (2,134)
(893,727) (66,679)
7 0.60 0.05
58
(893,727) (66,679)
429,445 (89,453)
429,445 (89,453)
(464,282) (156,132)
(457,148) (153,998)
(7,134) (2,134)
(464,282) (156,132)
59
653,163 430,081
284,103 135,999
3,125 3,125
41,305 34,166
11,712 21,423
– 304,675
28,042 50,951
1,021,450 980,420
65,322 9,918
8 127,825 45,273
95,344 116,145
313,290 317,059
8,697,927 5,928,716
9,299,708 6,417,111
9 118,597 84,602
4,242 6,831
727,552 204,886
7,757 12,647
20,112 20,336
1,197,168 –
2,075,428 329,302
7,224,280 6,087,809
8,245,730 7,068,229
– 1,200,564
35,439 47,442
287,761 37,693
278,203 123,611
601,403 1,409,310
7,644,327 5,658,919
23 19
7,597,078 5,604,540
7,597,101 5,604,559
47,226 54,360
7,644,327 5,658,919
60
1.
Ogier Global (Cayman)Limited, 89 Nexus Way, Camana Bay, Grand Cayman KY1-
9009 Cayman Islands
1 100% –
1 – 100%
InnoCare Pharma Inc. 10,000,000 – 100%
InnoCare Pharma Australia Pty Ltd. 10 – 100%
80,000,000 – 100%
(a)
10,000,000 – 100%
49,225,100 – 91.08%
4,000,000 – 100%
1,000,000,000 – 93%
30,000,000 – 100%
(a)
(a)
61
2.1
(a)
(b)
(c)
(i)
(ii) (iii) (i)
(ii) (iii)
62
2.2
3
16
37
1
9 16
41
(a) 3
3
37 21
3
37
21
(b) 16
2
(c) 37 37
(d)
1 9 16
41
9
63
2.3
10
28 3
16 2
17 1
17 1, 5
17 17
9 6
1 2, 4
1 2
1 1
2
8 1
12 1
1
2
3
4
5
5
17
4
39 9
6
17
10 28
10 28
10
28
16
16
64
1
12
12
1
2
1
2
8
12 12
12
7,852,000
7,877,000
65
3.
(a)
568,035 216,066
57,369 826,967
625,404 1,043,033
(b)
1,020,695 674,729
755 1,016
1,021,450 675,745
10%
A * 826,967
B 224,090 *
C 101,386 *
D 81,916 *
407,392 826,967
*
10%
4.
625,404 1,043,033
66
(a)
– 775,963
566,755 214,666
57,369 51,003
1,280 1,401
625,404 1,043,033
568,035 216,066
57,369 826,967
625,404 1,043,033
568,035 992,030
57,369 51,003
625,404 1,043,033
Biogen Inc.
MS
BTK
90
7,797 –
(b)
60
30 90
67
90
17,783 7,797
– 17,783
17,783 25,580
1
46,159 16,257
136,914 135,135
8,486 70
83 2,608
191,642 154,070
6,557 6,733
– 57,135
198,199 217,938
5.
68
16.5%
16.5%
2,000,000 2,000,000 8.25%
8.25% 16.5% 16. 5%
25% 15%
15% 15%
25%
50,000,000
25% 26% 50,000,000
30% 30%
21% 21%
– 52,593
– (6,035)
– 46,558
(893,727) (20,121)
25% (223,432) (5,030)
97,152 22,370
65,183 (23,565)
(62,491) (56,802)
– (82,003)
103,983 134,184
18,148 4,720
1,457 91
– 52,593
– 46,558
69
1,511,700,000
6.
7.
(886,593) (64,545)
1,479,565 1,366,261
70
8.
127,957 45,304
(132) (31)
127,825 45,273
127,822 45,273
3 –
127,825 45,273
31 –
100 32
1 –
– (1)
132 31
71
127,957 0.10% 132
45,304 0.07% 32
9.
111,186 84,459
7,335 121
66 17
10 5
118,597 84,602
90
10.
MS BTK
90
72
(www.hkexnews.hk)
(www.innocarepharma.com)
AD
ALL
AML
AQP4 IgG 4
ASH
B B B T
B
Biogen Biogen Inc. BIIB
BTD
BTK BTK
CD20 B CD20 MS4A1
B
CDC
CDE NMPA
73
CLL
CNSL
9969
DLBCL B
DLT
EULAR
FGFR
FL
GMP
74
IBD
ICP-105
ICP-192
ICP-022
iDMC
IL-2 -2
IL-5 -5
IL-12 -12
IL-23 -23
IND
IRC
ITK T
ITP
iwNHL
JAK
75
MCD B (DLBCL)
MYD88L265P CD79B MCD
MCL B
MS
MZL
NDA
MMOSD
NMPA
NRDL
NTRK
FGFR (FGFR)
TRK
PD
PK
76
R/R r/r
R-CHOP
RICE
264,648,217
SC
0.000002
SHP2 RAS
SLE
SLL
SRI SLE
T
T
T B NK
TDCC T
TRK
77
TYK2 2
UC
U.S.
FDA FDA
Vivo Vivo Opportunity Fund, L.P Vivo Capital VIII,
LLC
WM
78